Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ascendis Pharma A (ASND) Invested Capital (2016 - 2025)

Historic Invested Capital for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $825.3 million.

  • Ascendis Pharma A's Invested Capital rose 285.66% to $825.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $825.3 million, marking a year-over-year increase of 285.66%. This contributed to the annual value of $801.2 million for FY2025, which is 15.15% down from last year.
  • Per Ascendis Pharma A's latest filing, its Invested Capital stood at $825.3 million for Q4 2025, which was up 285.66% from $273.3 million recorded in Q3 2025.
  • In the past 5 years, Ascendis Pharma A's Invested Capital ranged from a high of $1.2 billion in Q3 2021 and a low of $94.1 million during Q2 2023
  • Over the past 5 years, Ascendis Pharma A's median Invested Capital value was $562.8 million (recorded in 2022), while the average stood at $543.5 million.
  • As far as peak fluctuations go, Ascendis Pharma A's Invested Capital tumbled by 8758.15% in 2023, and later surged by 8209.27% in 2024.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Invested Capital stood at $1.1 billion in 2021, then plummeted by 30.38% to $787.4 million in 2022, then tumbled by 31.87% to $536.4 million in 2023, then surged by 49.59% to $802.4 million in 2024, then increased by 2.86% to $825.3 million in 2025.
  • Its last three reported values are $825.3 million in Q4 2025, $273.3 million for Q3 2025, and $211.2 million during Q2 2025.